Ravulizumab: Characterization and quantitation of a new C5 inhibitor using isotype specific affinity purification and high-resolution mass spectrometry

INTRODUCTION: Ravulizumab (RAVUL) is a new complement inhibitor, with a difference of 4 amino acids in the heavy chain from a predecessor compound, eculizumab (ECUL). OBJECTIVES: First, to utilize mass spectrometry (MS) to characterize RAVUL and verify differences from its predecessor and, second, t...

Descripción completa

Detalles Bibliográficos
Autores principales: Ladwig, Paula M., Willrich, Maria A.V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8601004/
https://www.ncbi.nlm.nih.gov/pubmed/34820672
http://dx.doi.org/10.1016/j.jmsacl.2021.08.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8601004/
https://www.ncbi.nlm.nih.gov/pubmed/34820672
http://dx.doi.org/10.1016/j.jmsacl.2021.08.002

Ejemplares similares